CASE REPORT

Case Report: Stevens-Johnson syndrome following a single double dosing of nevirapine-containing regimen once in an HIV-infected woman on long-term antiretroviral therapy.

[version 1; peer review: 1 approved, 2 approved with reservations]

Betty Kakande1, Thuraya Isaacs1, Rudzani Muloiwa2, Sipho Dlamini3, Rannakoe Lehloenya1

1Division of Dermatology, Department of Medicine, University of Cape Town, Cape Town, 7700, South Africa
2Department of Paediatrics and Child Health, University of Cape Town, Cape Town, 7700, South Africa
3Division of Infectious Disease and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, 7700, South Africa

Abstract

A 31-year old HIV-infected African woman on nevirapine, tenofovir and lamivudine for more than 4 years presented with an 8-day history of symptoms and signs of Stevens-Johnson syndrome. She was on no other medication. Her viral load was undetectable and she had maintained a CD4 count of between 356 and 387 cells/mm3 in the preceding 2½ years. She missed her antiretrovirals 10 days before the onset of her symptoms and subsequently doubled her daily dose the following day. She had been on no other medication in the preceding 8 weeks.

Her ARVs were stopped and she fully re-epithelialized with the exception of the lips, over the following 10 days. She was started on a daily single tablet of Odimune® (a fixed drug combination antiretroviral containing tenofovir, emtricitabine and efavirenz).

Nevirapine is the most common offender in cases of antiretroviral-associated SJS in published literature. Lamivudine is very rarely implicated while there are no similar reports with tenofovir. We concluded that nevirapine was by far the most likely offender in this case. Nevirapine toxicity is associated with high CD4 counts, undetectable viral load and high drug plasma level. We postulate that the sudden increase of the plasma levels of nevirapine in a patient with a high CD4 count and undetectable viral load created a perfect storm for the development of SJS in our patient, who had been on the NVP-containing regimen for many years.
Clinicians should be aware that severe adverse drug reactions are dynamic and can occur even when the drug has been in use for a long time.

Keywords
HIV, nevirapine, double dose, Stevens-Johnson syndrome
Background
Nevirapine (NVP)-based antiretroviral regimens have been used widely in developing countries because of its affordability, availability and efficacy. NVP is also used to minimize diarrhea and cardiovascular side effects of protease inhibitors and neuropsychiatric side effects of Efavirenz. However, NVP is associated with severe adverse reactions, including Stevens-Johnson syndrome (SJS).

In larger series, the incubation period before developing features of SJS ranges from 10–240 days with a median duration of around 12 days. We report a case of probable nevirapine-associated Stevens-Johnson syndrome occurring more than 4 years after initiation of the drug. This case illustrates that in susceptible persons, a severe drug reaction can occur when there are dose adjustments despite having been exposed to the same drug for a long time.

Case report
A 31-year-old HIV-infected black African female presented with an 8-day history of painful swallowing, sore eyes, malaise and a worsening rash. She had been on antiretroviral (ARV) regimen of nevirapine (NVP) 400 mg daily, tenofovir 300 mg daily and lamivudine 300 mg daily for more than 4 years uneventfully. She was on no other medications and had not taken any other medication in the preceding 8 weeks. She had acquired HIV via heterosexual contact – the exact date of HIV infection was unknown. At the time of initiation of ARV therapy, her nadir CD4 cell count was 139 cells/mm$^3$ and her HIV RNA viral load at the time was unknown. Her last CD4 counts, done 31, 21 and 11 months before developing her current symptoms were 373, 356 and 387 cells/mm$^3$ respectively. The last HIV RNA viral load test, done 11 months prior to the onset of her symptoms showed an undetectable viral load.

She gave a history of forgetting to take her ARV medication for a day. The following day, 10 days before development of her symptoms she took 2 days equivalent of her ARVs in one day, in her own words “to make up for the missed dose”.

On examination, she was normotensive and had a temperature of 38.8°C. She had conjunctivitis and hemorrhagic cheilitis but no involvement of the genital mucosa. She had epidermal necrosis involving predominantly her trunk and face and to a lesser extent palms, soles and extremities, totaling 10% of her body surface area, 3% of which was stripping. Initial laboratory studies showed normal blood count, except for an elevated eosinophil count of 0.70 $\times$ 10$^3$/L. The liver and renal function tests were normal. Her ARVs were stopped and her epidermal necrosis did not extend and eosinophil counts normalized. Over the next few days her skin condition improved and she was discharged 10 days later fully re-epithelialized with the exception of the lips, which were still eroded in areas. On review, 2 weeks after discharge, her skin had normalized except for residual hyperpigmentation. She was started on a single daily tablet of Odimune®, a fixed drug combination of tenofovir 300 mg, emtricitabine 200 mg and efavirenz 600 mg. On follow-up, 4 weeks later she was tolerating the new ARV regimen.

Discussion
Clinicians routinely blame NVP as the culprit agent in cases of ARV-associated SJS as it is by far the most common offender in published literature. However, lamivudine has infrequently been reported as a cause of SJS, but there have not been similar reports with tenofovir. Based on these, we concluded that NVP was by far the most likely offender in our case.

Numerous factors have been associated with NVP toxicity, including high current and nadir CD4 counts, undetectable viral load, female sex, abnormally elevated baseline transaminases, history of drug allergy, lower body weight and high drug plasma levels. We postulate that the sudden increase of the plasma levels of NVP in a patient with a high CD4 count and undetectable viral load created a perfect storm for the development of SJS in our patient, who had been on the NVP-containing regimen for many years. The impact of NVP drug concentrations on the risk of adverse drug reactions is still controversial. Some studies have shown that above a certain threshold, the risk of severe drug reactions is significantly increased. A recent study has shown that impaired renal function, thus impaired clearance of the drug, is associated with an odds ratio of 8.0 (3.9 to 17) to develop allopurinol-associated SJS in susceptible people. However other studies have not found this association. NVP has a long half-life, 25–30 hours, and the effect of doubling the dose possibly increased the plasma drug concentrations considerably resulting in SJS.

The patient had been compliant on treatment for more than 4 years and had undetectable viral load and a high CD4 count the last time they were measured, 11 months earlier. Both of these are independent predictors of NVP-associated SJS. There were previous suggestions that the timing of SJS and other NVP-associated reactions coincided with the increase of the drug dose. However, this has been disproved, because as high as a third of cases in larger series occurred during the lead-in period of the dosing regimen before the dose was increased. Pretreatment with ARVs longer than 1 year has also been reported as an independent predictor of a cutaneous drug reaction. Whether this is truly an independent predictor or a result of low HIV viral load or higher CD4 counts is unclear and further studies are needed to answer this question.

In summary, this case highlights the potentially life-threatening risk of the development of SJS outside the expected period, probably triggered by a spike in serum levels of NVP. The case also illustrates that development of severe drug eruptions, like SJS, is a dynamic processes that may evolve with changing environment in the body. Clinicians should warn their patients against unregulated dosing changes of their NVP-containing regimen.

Consent
Written informed consent for publication of the clinical details was obtained from the patient.
Author contributions

BK, TI, RJL, and SD managed the patient. RJL, BK, RM and SD contributed to the preparation of the manuscript and revision of the draft manuscript. TI revised the final manuscript. All authors have agreed to the final content of the manuscript.

Competing interests

The authors have no competing interests to declare.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Tansuphaswadikul S, Aung SE, Phonrat B, et al.: Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Asian Pac J Allergy Immunol. 2007; 25(2–3): 147–154.

2. Kesselring AM, Wit FW, Sabin CA, et al.: Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. AIDS. 2009; 23(13): 1689–1699.

3. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, et al.: Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001; 15(14): 1843–1848.

4. Modak D, Guha SK: Severe skin rash with lamivudine in HIV infected patients: some unusual case reports. Indian J Pharmacol. 2013; 45(3): 298–300.

5. Ratanasuwan W, Jariyasethpong T, Anekthananon T, et al.: Association of Nevirapine Levels with Rash or Hepatotoxicity Among HIV-Infected Thai Women. Open AIDS J. 2012; 6: 266–273.

6. de Maat MM, ter Heine R, Mulder JW, et al.: Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol. 2002; 59(5–6): 457–462.

7. Chung WH, Chang WC, Stocker SL, et al.: Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis. 2014.

8. Kappelhoff BS, van Leth F, Robinson PA, et al.: Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther. 2006; 10(4): 489–498.

9. Dong BJ, Zheng Y, Hughes MD, et al.: Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. AIDS. 2012; 26(7): 833–841.

10. Kiertiburanakul S, Sungkanuparph S, Charoenyingwattana A, et al.: Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. Curr HIV Res. 2008; 6(1): 65–69.

11. Dziuban EJ, Hughey AB, Stewart DA, et al.: Stevens-Johnson syndrome and HIV in children in Swaziland. Pediatr Infect Dis J. 2013; 32(12): 1354–1358.
Ronald Kiguba  
Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda

The authors highlight an important report of Stevens-Johnson syndrome (SJS) in a patient on nevirapine-based antiretroviral therapy for more than two years. The median duration to the onset of nevirapine-associated SJS is two weeks, thus the case report stimulates exploration of the relationship between sudden rise in plasma nevirapine concentration and increased risk of SJS. However, it was not clear whether the authors performed any formal adverse drug reaction causality assessment, even though they stated that the reaction was "probable".

**Competing Interests:** No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Carla Ferrández-Pulido  
Department of Dermatology, Vall d'Hebron University Hospital, Barcelona, Spain

This is an interesting case of Stevens-Johnson syndrome probably due to a single double dosing of nevirapine-containing regimen in an HIV-infected woman. There have been a lot of case reports
and short series of SJS/TEN due to antiretroviral drugs. However, the singularity of this case is that the drug had been taken for a long time (4 years), and the triggering was an increase in the dosage. This side effect due to an increase in the dosage has also been reported for allopurinol.

Most of Lyell’s syndrome/TEN are caused by drugs; however, SJS may be triggered by a “new” drug or also an infection such as VHS/VVZ or Mycoplasma pneumoniae. In my opinion, it is always important to rule out such infections, when a SJS is suspected. This should be included in the article.

Some clinical images of the skin and mucosal involvement would improve the quality of the article.

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

---

**Reviewer Report 20 July 2015**

https://doi.org/10.5256/f1000research.7212.r9555

© 2015 Shear N. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Neil Shear**

Medical School, University of Toronto, Toronto, ON, Canada

The Title, Abstract and all content of the article are clear and relevant.

This case could seem to be simple but it actually adds a valuable perspective to our understanding of what might trigger severe drug reactions and adds clinical insights and clarity to what is often an overly complex environment.

**Competing Interests:** No competing interests were disclosed.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com